The drug company had posted a net profit of Rs 75 crore a year ago.
Net sales during the quarter grew marginally by 4% at Rs 1,079 crore against Rs 1,039 crore during the corresponding quarter of previous fiscal.
The company said that its US business, which made up 27% of the company's global revenues in the fourth quarter, declined 21% on a Y-o-Y basis.
The US business declined on expected lines due to restrictions of imports from Indian facilities, the company added.
Meanwhile, operating profit margins during the quarter under review stood at 12.6% against 11.8% in the previous year's corresponding quarter.
The stock opened at Rs 1,331 and touched a low of Rs 1,326 on the NSE. A combined 347,959 shares changed hands on the counter on the NSE and BSE till 0917 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)